Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15771
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.otherUniversidad San Pablo-CEU. Departamento de Ciencias Farmacéuticas y de la Salud-
dc.creatorOvejero Benito, María del Carmen-
dc.creatorMuñoz Aceituno, Ester-
dc.creatorReolid, Alejandra-
dc.creatorSaiz Rodríguez, Miriam-
dc.creatorAbad-Santos, Francisco-
dc.creatorDaudén, Esteban-
dc.date.accessioned2024-05-10T16:33:32Z-
dc.date.available2024-05-10T16:33:32Z-
dc.date.issued2017-09-18-
dc.identifier.citationOvejero-Benito, M.C., Muñoz-Aceituno, E., Reolid, A. et al. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. Am J Clin Dermatol 19, 209–222 (2018). https://doi.org/10.1007/s40257-017-0322-9es_ES
dc.identifier.issn1179-1888-
dc.identifier.urihttp://hdl.handle.net/10637/15771-
dc.description.abstractPharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis. Psoriasis is a chronic inflammatory disease with an autoimmune contribution. Although its etiology remains unknown, genetic, epigenetic, and environmental factors play a role in its development. Diverse systemic and biologic therapies are used to treat moderate-to-severe psoriasis. However, these treatments are not curative, and patients exhibit a wide range of responses to them. Moderate-to-severe psoriasis is usually treated with systemic immunomodulators such as acitretin, ciclosporin, and methotrexate. Anti-tumor necrosis factor (TNF) drugs (adalimumab, etanercept, or infliximab) are the first-line treatment for patients resistant to conventional systemic therapies. Although these therapies are very efficient, around 30–50% of patients have inadequate response. Ustekinumab is a monoclonal antibody that targets interleukin (IL)-12 and IL-23 and is used for moderate-to-severe psoriasis. New drugs (apremilast, brodalumab, guselkumab, ixekizumab, and secukinumab) have recently been approved for psoriasis. However, response rates to systemic treatments for moderate-to-severe psoriasis range from 35 to 80%, so it is necessary to identify non-invasive biomarkers that could help predict treatment outcomes of these therapies and individualize care for patients with psoriasis. These biomarkers could improve patient quality of life and reduce health costs and potential side effects. Pharmacogenetic studies have identified potential biomarkers for response to biologic treatments for moderate-to-severe psoriasis. These biomarkers need to be validated in clinical trials involving large cohorts of patients before they can be translated to the clinic. We review pharmacogenetics and pharmacogenomics studies for the treatment of moderate-to-severe plaque psoriasis.es_ES
dc.language.isoenes_ES
dc.publisherSpringer Linkes_ES
dc.relation.ispartofAmerican Journal of Clinical Dermatology-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.es-
dc.titlePharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasises_ES
dc.typeArtículoes_ES
dc.identifier.doi10.1007/s40257-017-0322-9-
dc.centroUniversidad San Pablo-CEU-
Aparece en las colecciones: Facultad de Farmacia




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.